New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareVesugen vs DSIP

Vesugen vs DSIP

Side-by-side comparison of key properties, dosing, and research.

Anti-Aging & Longevity
Vesugen
Sleep OptimizationCognitive Enhancement
DSIP
Summary
Vesugen is a tripeptide bioregulator (Lys-Glu-Asp) developed by Professor Vladimir Khavinson, tissue-specific for blood vessels and the vascular endothelium. It supports endothelial cell function, promotes vascular wall integrity, and is studied for atherosclerosis prevention, vascular aging, and cardiovascular health maintenance. It is one of the more broadly applicable Khavinson bioregulators given the ubiquity of vascular tissue.
DSIP is an endogenous neuropeptide originally isolated from rabbit cerebrospinal fluid that induces delta-wave (deep) sleep. It also modulates stress response, cortisol regulation, and LH secretion, making it valuable for sleep optimization and stress management.
Half-Life
Short (minutes); sustained gene-regulatory effects
~30–60 minutes; however downstream sleep effects last 4–6 hours
Admin Route
SubQ, Oral
SubQ, IV, Intranasal
Research
Typical Dose
10 mg per day
100–400 mcg
Frequency
Daily for 10–30 days
Once nightly
Key Benefits
  • Supports vascular endothelial cell function and integrity
  • May reduce endothelial inflammation and dysfunction
  • Anti-aging effects on blood vessel walls
  • Potential benefits in early atherosclerosis and vascular aging
  • Supports nitric oxide-mediated vascular tone
  • Reduces endothelial apoptosis from oxidative stress
  • Complementary to Cardiogen and Epithalon in cardiovascular longevity protocols
  • Induces and deepens delta-wave (slow-wave) sleep
  • Reduces cortisol and normalizes HPA axis
  • Improves sleep quality in insomnia patients
  • Anti-stress and anxiolytic effects
  • May improve opiate/alcohol withdrawal symptoms
  • Analgesic properties through opioid modulation
  • Antioxidant and neuroprotective effects
Side Effects
  • Generally well tolerated
  • Mild injection site reactions
  • No significant vascular adverse events reported at standard doses
  • Generally well tolerated
  • Mild grogginess next morning at higher doses
  • Rare: hypotension
  • Potential for altered dream patterns
Stacks With